BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 9067281)

  • 1. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
    Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
    Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J; Gaumont Y; Kisliuk RL; Sirotnak FM; Murthy BR; Nair MG; Piper JR
    Cancer Res; 1989 Jan; 49(1):158-63. PubMed ID: 2521177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
    Schultz RM; Patel VF; Worzalla JF; Shih C
    Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
    Gangjee A; Jain HD; McGuire JJ; Kisliuk RL
    J Med Chem; 2004 Dec; 47(27):6730-9. PubMed ID: 15615522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP; Moran RG
    Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.